AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT00547417
Drug: tadalafil
RxNorm normalized name: Tadalafil
DrugBank: Tadalafil (DB00820)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 20 mg tadalafil tablet taken by mouth, as needed, no more than once a day, for 12 weeks.
Trial: NCT03027245
Drug: Eribulin
RxNorm normalized name: Eribulin
DrugBank: Eribulin (DB08871)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT00571116
Drug: Arsenic trioxide
RxNorm normalized name: Arsenic Trioxide
DrugBank: Arsenic trioxide (DB01169)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Given IV
Trial: NCT00285376
Drug: vilazodone
RxNorm normalized name: Vilazodone
DrugBank: Vilazodone (DB06684)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: titration to 40mg tablets qd for 8 weeks
Trial: NCT00575471
Drug: Rivoglitazone HCl
RxNorm normalized name: Pioglitazone Hydrochloride
DrugBank: Rivoglitazone (DB09200)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 mg tablets once daily for 12 weeks
Trial: NCT00575471
Drug: rivoglitazone HCl
RxNorm normalized name: Pioglitazone Hydrochloride
DrugBank: Rivoglitazone (DB09200)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.0 mg tablets once daily for 12 weeks
Trial: NCT00575471
Drug: rivoglitazone HCl
RxNorm normalized name: Pioglitazone Hydrochloride
DrugBank: Rivoglitazone (DB09200)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.5 mg tablets once daily for 12 weeks
Trial: NCT02932605
Drug: Cannabidiol
RxNorm normalized name: CANNABIDIOL
DrugBank: Cannabidiol (DB09061)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Cannabidiol
Trial: NCT02004314
Drug: Chloroquine
RxNorm normalized name: Chloroquine
DrugBank: Chloroquine (DB00608)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT04575584
Drug: Molnupiravir
RxNorm normalized name: Molnupiravir
DrugBank: Molnupiravir (DB15661)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: Molnupiravir administered orally in capsule form every 12 hours for 5 days (10 doses total)
Trial: NCT02865629
Drug: N-acetyl cysteine
RxNorm normalized name: N-Acetyl Cysteine
DrugBank: Acetylcysteine (DB06151)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: N-acetylcysteine will be initiated at 600 mg PO daily for Week 1, then increased to 600 mg PO twice a day for Week 2, then increased to 600 mg PO morning and 1200 mg PO evening for Week 3, and then increased to 1200 mg PO twice a day for Week 4-8. Doses might be decreased anytime if clinically indicated. Following the study, all patients will be referred to treatment as usual. Adherence will be assessed in weekly visits in the first month and then bi-weekly in the second month. Adherence will be assessed by subject interview, pill counts during each study visit, and by legal guardian interview (if minor).
Trial: NCT00568893
Drug: drotrecogin alfa (activated)
RxNorm normalized name: DROTRECOGIN ALFA (ACTIVATED)
DrugBank: Drotrecogin alfa (DB00055)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01756339
Drug: Solithromycin
RxNorm normalized name: solithromycin
DrugBank: Solithromycin (DB09308)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01756339
Drug: Moxifloxacin
RxNorm normalized name: Moxifloxacin
DrugBank: Moxifloxacin (DB00218)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03739801
Drug: Liposomal Irinotecan
DrugBank: Irinotecan (DB00762)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT02653898
Drug: Primaquine
RxNorm normalized name: Primaquine
DrugBank: Primaquine (DB01087)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 22.5 mg weekly for 12 weeks in the MMP arm; low dose primaquine (15mg) for transmission blocking of P. falciparum or 14 days of primaquine (15mg) in G6PD normal volunteers or 8 weeks of low dose primaquine (45mg) in G6PD-deficient volunteers for radical cure of P. vivax
Trial: NCT02653898
Drug: Artesunate + Mefloquine
RxNorm normalized name: artesunate and mefloquine
DrugBank: Mefloquine (DB00358)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Weight based; first line agent for P.f malaria infection diagnosed at monthly follow ups, administered on days 1-3 in subjects with malaria recurrence
Trial: NCT02653898
Drug: Permethrin (Insecticide treated uniform)
RxNorm normalized name: Permethrin
DrugBank: Permethrin (DB04930)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 40% Permethrin IDA kit, applied once to the uniforms for volunteers assigned to ITU arm
Trial: NCT00004197
Drug: mitoxantrone hydrochloride
RxNorm normalized name: Mitoxantrone Hydrochloride
DrugBank: Mitoxantrone (DB01204)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00004197
Drug: prednisone
RxNorm normalized name: Prednisone
DrugBank: Prednisone (DB00635)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00004197
Drug: vincristine sulfate
RxNorm normalized name: Vincristine Sulfate
DrugBank: Vincristine (DB00541)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01955577
Drug: Vitamin D3 cholecalciferol
DrugBank: Cholecalciferol (DB00169)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04293172
Drug: Brilinta
RxNorm normalized name: Brilinta
DrugBank: Ticagrelor (DB08816)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients in the open-label Run-in period (patients aged 6 to \<24 months only) will receive ticagrelor 5 mg twice a day (body weight 6 to ≤9 kg), 10 mg twice a day (body weight \>9 to ≤12 kg) or 15 mg twice a day (body weight \>12 to ≤24 kg) for 14 days.~The double-blind IP will be based on 5 weight bands:~* 6 to ≤9 kg: ticagrelor 5 mg or matching placebo, twice a day~* \>9 to ≤12 kg: ticagrelor 10 mg or matching placebo, twice a day~* \>12 to ≤24 kg: ticagrelor 15 mg or matching placebo, twice a day~* \>24 to ≤48 kg: ticagrelor 30 mg or matching placebo, twice a day~* \>48 kg: ticagrelor 45 mg or matching placebo, twice a day
Trial: NCT02527317
Drug: Lipegfilgrastim
RxNorm normalized name: Lipegfilgrastim
DrugBank: Lipegfilgrastim (DB13200)
FDA approved: no
EMA approved: yes
PMDA approved: no
Description: Investigate the incidence of treatment-related neutropenia following four cycles of dose dense (every 2 week) doxorubicin cyclophosphamide (AC) with lipegfilgrastim support (8 weeks).
Trial: NCT00715520
Drug: Carbidopa-Levodopa
RxNorm normalized name: Carbidopa-Levodopa
DrugBank: Carbidopa (DB00190)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants will receive one oral dose of carbidopa-levodopa 25mg one hour prior to measuring wrist extension movements.~The order in which Carbidopa-Levodopa is given will be randomized per participant.
Trial: NCT00715520
Drug: Methylphenidate
RxNorm normalized name: Methylphenidate
DrugBank: Methylphenidate (DB00422)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants will receive one oral dose of methylphenidate 40mg 2 hours prior to measuring wrist extension movements.~The order in which Methylphenidate is given will be randomized per participant.
Trial: NCT00715520
Drug: Amphetamine Sulfate
RxNorm normalized name: amphetamine sulfate
DrugBank: Amphetamine (DB00182)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive one oral dose of amphetamine sulfate 10mg 2 hours prior to measuring wrist extension movements.~The order in which Amphetamine Sulfate is given will be randomized per participant.
Trial: NCT00146549
Drug: Trastuzumab
RxNorm normalized name: trastuzumab
DrugBank: Trastuzumab (DB00072)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT00146549
Drug: Vinorelbine
RxNorm normalized name: Vinorelbine
DrugBank: Vinorelbine (DB00361)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00146549
Drug: Paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT00146549
Drug: Docetaxel
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02711943
Drug: Levofloxacin 500
RxNorm normalized name: levofloxacin 500 MG
DrugBank: Levofloxacin (DB01137)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral levofloxacin (Levolet®) at a dose of 500 mg once a day for 28 days
Trial: NCT03208413
Drug: Thalidomide
RxNorm normalized name: Thalidomide
DrugBank: Thalidomide (DB01041)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Thalidomide with a dosage of 25 mg at bedtime daily one week (days 1-7), then 50 mg at bedtime daily for one week (days 8-14), then 75 mg at bedtime daily for one week (days 15-21), then 100 mg at bedtime daily for 12 weeks (days 22-105), in the absence of unacceptable toxicity or severe deterioration.
Trial: NCT03564093
Drug: Intranasal Drug
RxNorm normalized name: NALOXONE RESCUE KIT INTRANASAL
DrugBank: Naloxone (DB01183)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1µg/kg of dexmedetomidine is given 30 minutes prior to intravenous cannulation or lumbar puncture
Trial: NCT03564093
Drug: Intranasal Drug
RxNorm normalized name: NALOXONE RESCUE KIT INTRANASAL
DrugBank: Naloxone (DB01183)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intranasal 4,5% saline is given as a placebo 30 minutes prior to intravenous cannulation or lumbar puncture
Trial: NCT04480996
Drug: Drugs Responsible for Cognitive Side Effects
RxNorm normalized name: cured fat, pork side bacon
DrugBank: Pork (DB10561)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: identification of road traffic accidents associated with drugs responsible for psychomotor side effects
Trial: NCT03832673
Drug: Pembrolizumab
RxNorm normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Pembrolizumab 200 mg IV every 3 weeks (for 3 cycles)
Trial: NCT03832673
Drug: Epacadostat
RxNorm normalized name: epacadostat
DrugBank: Epacadostat (DB11717)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epacadostat 300 mg (BID) orally continuously every 28 days (for 3 cycles)
Trial: NCT00496587
Drug: Gemcitabine
RxNorm normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 900 mg/m\^2 By Vein Over 30 Minutes on Days 1 and 15.
Trial: NCT00496587
Drug: Bevacizumab
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 10 mg/kg By Vein On Days 1 and 15.
Trial: NCT04848246
Drug: Bupropion
RxNorm normalized name: Bupropion
DrugBank: Bupropion (DB01156)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: This group received Bupropion 150 mg twice daily for 10 weeks
Trial: NCT01515696
Drug: Gastrografin
RxNorm normalized name: Gastrografin
DrugBank: Diatrizoate (DB00271)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients will receive 3ml Gastrografin + 6ml sterile water/kg as a single dose via a nasogastric tube during the first 24 hours of life.
Trial: NCT01515696
Drug: Sterile water
RxNorm normalized name: sterile water
DrugBank: Water (DB09145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will receive 9ml/kg sterile water as a single dose via a nasogastric tube during the first 24 hours of life.
Trial: NCT00004088
Drug: busulfan
RxNorm normalized name: Busulfan
DrugBank: Busulfan (DB01008)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00004088
Drug: melphalan
RxNorm normalized name: Melphalan
DrugBank: Melphalan (DB01042)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00004088
Drug: pamidronate disodium
RxNorm normalized name: Pamidronate Disodium
DrugBank: Pamidronic acid (DB00282)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00004088
Drug: thalidomide
RxNorm normalized name: Thalidomide
DrugBank: Thalidomide (DB01041)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT03630029
Drug: FeS and SnPP
RxNorm normalized name: cytarabine and daunorubicin
DrugBank: Daunorubicin (DB00694)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Escalating doses of drug will be compared for biomarker changes
Trial: NCT02445742
Drug: Bosutinib
RxNorm normalized name: Bosutinib
DrugBank: Bosutinib (DB06616)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 500 mg/day of Bosutinib during the study until disease progression, unacceptable toxicity, or withdrawal of consent occurs
Trial: NCT04483297
Drug: AK1320 MS
RxNorm normalized name: MS-1819
DrugBank: MS-1819 (DB15004)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AK1320 MS + Local Autologous Bone + Posterior Fixation. Ascending Dose.
Trial: NCT00005796
Drug: lomustine
RxNorm normalized name: Lomustine
DrugBank: Lomustine (DB01206)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: chemotherapy is administered every 21 days
Trial: NCT00005796
Drug: procarbazine hydrochloride
RxNorm normalized name: Procarbazine Hydrochloride
DrugBank: Procarbazine (DB01168)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: chemotherapy is administered every 21 days.
Trial: NCT00005796
Drug: vincristine sulfate
RxNorm normalized name: Vincristine Sulfate
DrugBank: Vincristine (DB00541)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: chemotherapy is administered every 21 days
Trial: NCT03706469
Drug: TAK-831 T3
RxNorm normalized name: T3
DrugBank: Liothyronine (DB00279)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: TAK-831 T3 Tablets.
Trial: NCT00895934
Drug: vorinostat
RxNorm normalized name: Vorinostat
DrugBank: Vorinostat (DB02546)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given orally
Trial: NCT00510484
Drug: Pancrelipase Delayed Release
RxNorm normalized name: Pancrelipase Delayed-Release Capsules
DrugBank: Pancrelipase (DB00085)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 24000 unit Capsule
Trial: NCT00895934
Drug: gemtuzumab ozogamicin
RxNorm normalized name: Gemtuzumab Ozogamicin
DrugBank: Gemtuzumab ozogamicin (DB00056)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Given intravenously (IV)
Trial: NCT00895934
Drug: azacitidine
RxNorm normalized name: Azacitidine
DrugBank: Azacitidine (DB00928)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Given IV or subcutaneously (SC)
Trial: NCT00000290
Drug: Cocaine
RxNorm normalized name: Cocaine
DrugBank: Cocaine (DB00907)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00560898
Drug: ProClear Lens Material soaked in ReNu Multiplus Multipurpose Solution
RxNorm normalized name: lens scale pollen extract
DrugBank: Atriplex lentiformis pollen (DB10760)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Contact lens soaked in multipuprpose solution for 8 hours, then worn for two hours
Trial: NCT00560898
Drug: Acuvue Advance Lens Material soaked in ReNu Multiplus Multipurpose Solution
RxNorm normalized name: lens scale pollen extract
DrugBank: Atriplex lentiformis pollen (DB10760)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Contact lens soaked in multipuprpose solution for 8 hours, then worn for two hours
Trial: NCT00560898
Drug: Acuvue Advance Lens Material soaked in Optifree RepleniSH Multipurpose Solution
RxNorm normalized name: lens scale pollen extract
DrugBank: Atriplex lentiformis pollen (DB10760)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Contact lens soaked in multipuprpose solution for 8 hours, then worn for two hours
Trial: NCT00560898
Drug: ProClear Lens Material soaked in Optifree RepleniSH Multipurpose Solution
RxNorm normalized name: lens scale pollen extract
DrugBank: Atriplex lentiformis pollen (DB10760)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Contact lens soaked in multipuprpose solution for 8 hours, then worn for two hours
Trial: NCT01331135
Drug: sirolimus
RxNorm normalized name: Sirolimus
DrugBank: Sirolimus (DB00877)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: daily administration of sirolimus in oral form starting at a dose of 1 mg/m2 and increasing to a possible 3 mg/m2.
Trial: NCT00351936
Drug: Aripiprazole
RxNorm normalized name: Aripiprazole
DrugBank: Aripiprazole (DB01238)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT01309451
Drug: Bevacizumab
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: intravitreal, 1.25mg., monthly
Trial: NCT01309451
Drug: dexamethasone intravitreal implant
RxNorm normalized name: Dexamethasone Intravitreal Implant
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 0.7mg, intravitreal every 4 months
Trial: NCT02481180
Drug: T0001
RxNorm normalized name: Tadalafil
DrugBank: Tadalafil (DB00820)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: injection (SC) T0001 15mg weekly for 12 weeks
Trial: NCT02481180
Drug: T0001
RxNorm normalized name: Tadalafil
DrugBank: Tadalafil (DB00820)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: injection (SC) T0001 30mg weekly for 12 weeks
Trial: NCT02481180
Drug: T0001
RxNorm normalized name: Tadalafil
DrugBank: Tadalafil (DB00820)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: injection (SC) T0001 30mg every two weeks for 12 weeks
Trial: NCT02481180
Drug: T0001
RxNorm normalized name: Tadalafil
DrugBank: Tadalafil (DB00820)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: injection (SC) T0001 50mg every two weeks for 12 weeks
Trial: NCT02481180
Drug: Enbrel
RxNorm normalized name: Enbrel
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: injection (SC) enbrel 50mg twice a week for 12 weeks
Trial: NCT01723020
Drug: AMG 232
RxNorm normalized name: AMG 108
DrugBank: AMG 108 (DB05545)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given an an oral tablet in escalating doses.
Trial: NCT00591019
Drug: Modafinil
RxNorm normalized name: Modafinil
DrugBank: Modafinil (DB00745)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 200 mg/day, morning dose
Trial: NCT01054313
Drug: Docetaxel (Taxotere)
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Starting dose 30 mg/m\^2 by vein (IV) over about 1 hour on Day 1 of every 21 day cycle.
Trial: NCT01054313
Drug: Sirolimus (Rapamycin)
RxNorm normalized name: Sirolimus
DrugBank: Sirolimus (DB00877)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Starting dose 1 mg daily by mouth 1 time a day.
Trial: NCT01054313
Drug: Prednisone
RxNorm normalized name: Prednisone
DrugBank: Prednisone (DB00635)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 5 mg by mouth twice a day with prostate cancer.
Trial: NCT00005896
Drug: filgrastim
RxNorm normalized name: Filgrastim
DrugBank: Filgrastim (DB00099)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT03462719
Drug: Ibrutinib
RxNorm normalized name: Ibrutinib
DrugBank: Ibrutinib (DB09053)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Participants will receive ibrutinib 420 mg orally once daily up to 15 cycles.
Trial: NCT03462719
Drug: Venetoclax
RxNorm normalized name: Venetoclax
DrugBank: Venetoclax (DB11581)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Participants will receive venetoclax in combination with ibrutinib for a total of 12 cycles, beginning at Cycle 4. For the first 5 weeks of venetoclax treatment, the treatment dose will be ramped up from 20 to 400 mg.
Trial: NCT03462719
Drug: Chlorambucil
RxNorm normalized name: Chlorambucil
DrugBank: Chlorambucil (DB00291)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants will receive chlorambucil at a dose of 0.5 mg/kg body weight on Days 1 and 15 of Cycles 1 to 6.
Trial: NCT03462719
Drug: Obinutuzumab
RxNorm normalized name: Obinutuzumab
DrugBank: Obinutuzumab (DB08935)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Participant will receive obinutuzumab 1000 mg intravenously on Days 1, 8, and 15 of Cycle 1, and Day 1 of Cycles 2 to 6.
Trial: NCT03462719
Drug: Ibrutinib (as Subsequent Therapy)
RxNorm normalized name: Ibrutinib
DrugBank: Ibrutinib (DB09053)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Participants will receive ibrutinib 420 mg orally once daily until disease progression or unacceptable toxicity during the subsequent therapy phase.
Trial: NCT03006848
Drug: Avelumab
RxNorm normalized name: Avelumab
DrugBank: Avelumab (DB11945)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Patients will be administered avelumab at a dose of 10 mg/kg intravenously (IV) over 60 minutes on days 1 and 15 of each cycle, with a cycle lasting 28 days. Patients will receive avelumab every 2 weeks in cycles of 28 days for up to 24 months, or 26 cycles.
Trial: NCT00670657
Drug: AmBisome
RxNorm normalized name: AmBisome
DrugBank: Amphotericin B (DB00681)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients will receive 2mg/kg/day IV daily administration of AmBisome® over 30-60 minutes as a reaction to signs/symptoms and positive Candida culture
Trial: NCT00869973
Drug: Aprepitant
RxNorm normalized name: Aprepitant
DrugBank: Aprepitant (DB00673)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aprepitant 80 mg orally: 24 hours after chemotherapy on day 2 and then at 8 am on day 3
Trial: NCT00869973
Drug: dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: dexamethasone 4 mg orally: 24 hours after chemotherapy and at 8 pm on day 2, then at 8 am and 8 pm on day 3
Trial: NCT01111682
Drug: Mannitol
RxNorm normalized name: Mannitol
DrugBank: Mannitol (DB00742)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 0.9% normal saline infusion and boluses of mannitol
Trial: NCT00528073
Drug: Rifaximin-EIR
RxNorm normalized name: Rifaximin
DrugBank: Rifaximin (DB01220)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Comparison of 800 mg, 1600 mg and 2400 mg Rifaximin-EIR versus placebo in the treatment of active moderate Crohn's disease
Trial: NCT02741466
Drug: Coppertone (BAY987517)
DrugBank: Copper (DB09130)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application. Formulation number - SR16-01.
Trial: NCT01420042
Drug: NNZ-2566
RxNorm normalized name: NNZ-2591
DrugBank: NNZ-2591 (DB15601)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glycyl-L-2-Methylprolyl-L-Glutamic Acid (NNZ-2566) supplied as a lyophilized powder (2g in 50mL vials) for reconstitution with lemon flavoured cordial and Water for Injection.
Trial: NCT00099632
Drug: Emtricitabine/Tenofovir Disoproxil Fumarate
RxNorm normalized name: Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate
DrugBank: Tenofovir disoproxil (DB00300)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 200mg/300mg as one tablet taken orally once daily
Trial: NCT00099632
Drug: Lamivudine/Zidovudine
RxNorm normalized name: LAMIVUDINE/ZIDOVUDINE
DrugBank: Zidovudine (DB00495)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 150mg/300mg as one tablet taken orally twice daily
Trial: NCT00099632
Drug: Lopinavir/Ritonavir
RxNorm normalized name: LOPINAVIR/RITONAVIR
DrugBank: Ritonavir (DB00503)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 133.3mg/33.3mg as three capsules taken orally twice daily